Established · publishing since 1998
Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsAcute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia ResearchNeutropenia and Cancer Infections
Publications
196
Citations
7,515
Est. group size
~5
Recurring co-author estimate
Active years
29
Publishing since 1998
In context
Among 4,953 established Medicine PIs within our index
Citations: 7,515p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 7.0p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~16 · 14% small-team papers (≤3 authors) · across 12 venues
Publication cadence
Publications per year over the last 10 years — averaging 7.0/year recently
Recent publications
- Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias
2025
- Data from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i>-ITD Mutant/<i>TP53</i> Wild-type Acute Myeloid Leukemias
2025
- Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia
Blood Cancer Journal · 2025
- Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in <i>FLT3</i> -ITD Mutant/ <i>TP53</i> Wild-type Acute Myeloid Leukemias
Clinical Cancer Research · 2025
- A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Clinical Lymphoma Myeloma & Leukemia · 2024
- AML-385 A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Clinical Lymphoma Myeloma & Leukemia · 2024
- Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)
Blood · 2023
- Targeting <i>RARA</i> overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Blood Advances · 2022
- Assessing the Role of BCOR/BCORL1 and Other Historically Low-Frequency Somatic Mutations in Myelodysplastic Syndromes
Blood · 2021
- CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
The Lancet Haematology · 2021
- Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia
Blood · 2021
- Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.
Journal of Clinical Oncology · 2020
- A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia
Blood · 2020
- Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
Blood · 2020
- Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b
Blood · 2019
Publishes in
- Blood×36
- Clinical Lymphoma Myeloma & Leukemia×12
- Journal of Clinical Oncology×11
- Leukemia & lymphoma/Leukemia and lymphoma×9
- Journal of the National Comprehensive Cancer Network×5
Similar researchers
By research-topic overlap
- Annette S. Kim
Medicine · University of Michigan
- Terri Guinipero
Medicine · The Ohio State University
- Yosra Ben Youssef
Medicine · The Ohio State University
- C. D. Bloomfield
Medicine · The Ohio State University
- Larry D. Cripe
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile